Malignant pleural mesothelioma (MPM) - Pipeline Insight, 2021

July 2021 | 70 pages | ID: MD8E36B7AB39EN
DelveInsight

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight’s, “Malignant pleural mesothelioma (MPM) - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Malignant pleural mesothelioma (MPM) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Malignant pleural mesothelioma (MPM) Understanding

Malignant pleural mesothelioma (MPM): Overview

Malignant pleural mesothelioma is a cancer that develops in the pleura, the thin tissue lining the lungs. Symptoms of pleural mesothelioma include chest pain, coughing and pleural effusion. The cause of pleural mesothelioma is exposure to asbestos fibers, which a person can inhale into the lungs. Diagnosis of malignant pleural mesothelioma includes multiple tests such as an X-ray or CT scan, blood tests, and biopsy to verify a malignant pleural mesothelioma diagnosis. The standard pleural mesothelioma treatment options include surgery, radiation therapy and chemotherapy. Emerging treatments include novel therapies such as immunotherapy, gene therapy and photodynamic therapy to treat pleural mesothelioma.

'Malignant pleural mesothelioma (MPM) - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Malignant pleural mesothelioma (MPM) pipeline landscape is provided which includes the disease overview and Malignant pleural mesothelioma (MPM) treatment guidelines. The assessment part of the report embraces, in depth Malignant pleural mesothelioma (MPM) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Malignant pleural mesothelioma (MPM) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Malignant pleural mesothelioma (MPM) R&D. The therapies under development are focused on novel approaches to treat/improve Malignant pleural mesothelioma (MPM).

Malignant pleural mesothelioma (MPM) Emerging Drugs Chapters

This segment of the Malignant pleural mesothelioma (MPM) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Malignant pleural mesothelioma (MPM) Emerging Drugs

• REIC gene therapy: Momotaro-Gene

REIC gene therapy is a novel investigational gene therapy with unique dual mechanisms of action. The drug candidate leverages the company’s proprietary adenoviral vector technology platform to deliver the Reduced Expression in Immortalized Cells/Dickkopf-3 gene (REIC/Dkk-3 gene) into cancer cells, where the expression of the gene has been shown to be markedly downregulated. The resulting increase in REIC/Dkk-3 gene expression in cancer cells triggers immunogenic cell death selectively in cancer cells. The drug is in Phase II clinical studies for the treatment of malignant pleural mesothelioma (MPM).

• ONCOS-102: Targovax

ONCOS-102 is an experimental adenovirus-based cancer therapy. The drug is in Phase II clinical studies for the treatment of malignant pleural mesothelioma (MPM). In January 2015, the US FDA granted orphan drug designation to ONCOS 102 for the treatment of malignant mesothelioma.

Further product details are provided in the report……..

Malignant pleural mesothelioma (MPM): Therapeutic Assessment

This segment of the report provides insights about the different Malignant pleural mesothelioma (MPM) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Malignant pleural mesothelioma (MPM)

There are approx. 20+ key companies which are developing the therapies for Malignant pleural mesothelioma (MPM). The companies which have their Malignant pleural mesothelioma (MPM) drug candidates in the most advanced stage, i.e. Phase II include, Targovax.

• Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Malignant pleural mesothelioma (MPM) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Malignant pleural mesothelioma (MPM): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Malignant pleural mesothelioma (MPM) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Malignant pleural mesothelioma (MPM) drugs.

Malignant pleural mesothelioma (MPM) Report Insights

• Malignant pleural mesothelioma (MPM) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Malignant pleural mesothelioma (MPM) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Malignant pleural mesothelioma (MPM) drugs?
• How many Malignant pleural mesothelioma (MPM) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Malignant pleural mesothelioma (MPM)?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Malignant pleural mesothelioma (MPM) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Malignant pleural mesothelioma (MPM) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Momotaro-Gene
• Ys Therapeutics
• MedImmune
• TCR2 Therapeutics
• Atara Biotherapeutics
• Inhibrx
• Eisai
• Targovax
• Merck & Co
• Bayer HealthCare
• SELLAS Life Sciences Group
• CanBas
• Johnson & Johnson
• Sumitomo Dainippon Pharma Oncology
• FKD Therapies
• Virttu Biologics
• MolMed

Key Products

• REIC gene therapy
• YS 110
• Tremelimumab
• TC 210
• ATA 2271
• INBRX 109
• Amatuximab
• ONCOS 102
• Pembrolizumab
• BAY-94-9343
• Galinpepimut S
• CBP 501
• Trabectedin
• Napabucasin
• Nadofaragene firadenovec
• HSV 1716
• NGR-TNF MolMed

Contents

Introduction
Executive Summary
Malignant pleural mesothelioma (MPM): Overview
  Causes
  Mechanism of Action
  Signs and Symptoms
  Diagnosis
  Disease Management
Pipeline Therapeutics
  Comparative Analysis
Therapeutic Assessment
  Assessment by Product Type
  Assessment by Stage and Product Type
  Assessment by Route of Administration
  Assessment by Stage and Route of Administration
  Assessment by Molecule Type
  Assessment by Stage and Molecule Type
Malignant pleural mesothelioma (MPM) – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
  Comparative Analysis
NGR-TNF: MolMed
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
  Comparative Analysis
REIC gene therapy: Momotaro-Gen
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
  Comparative Analysis
HSV 1716: Virttu Biologics
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
  Comparative Analysis
Drug name: Company name
  Product Description
  Research and Development
  Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
  Comparative Analysis
Malignant pleural mesothelioma (MPM) Key Companies
Malignant pleural mesothelioma (MPM) Key Products
Malignant pleural mesothelioma (MPM)- Unmet Needs
Malignant pleural mesothelioma (MPM)- Market Drivers and Barriers
Malignant pleural mesothelioma (MPM)- Future Perspectives and Conclusion
Malignant pleural mesothelioma (MPM) Analyst Views
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Malignant pleural mesothelioma (MPM)
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Malignant pleural mesothelioma (MPM)
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products